Two Sigma Advisers’s Arcturus Therapeutics ARCT Stock Holding History

Two Sigma Advisers’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-511,043	Closed	-$3.13M	–	156
2025 Q4	$3.13M	Buy	511,043 +472,543	+1,227%	+$5.1M	0.01%	1004
2025 Q3	$710K	Sell	38,500 -10,000	-21%	-$161K	﹤0.01%	1616
2025 Q2	$631K	Buy	+48,500	New	+$574K	﹤0.01%	1647
2021 Q3	–	Sell	-320,343	Closed	-$10.8M	–	2433
2021 Q2	$10.8M	Buy	320,343 +48,000	+18%	+$1.62M	0.03%	536
2021 Q1	$11.2M	Buy	272,343 +96,700	+55%	+$5.76M	0.03%	530
2020 Q4	$7.62M	Buy	175,643 +17,800	+11%	+$1.21M	0.02%	662
2020 Q3	$6.77M	Buy	157,843 +48,600	+44%	+$2.41M	0.02%	661
2020 Q2	$5.11M	Buy	109,243 +60,300	+123%	+$2.08M	0.02%	784
2020 Q1	$665K	Sell	48,943 -100	-0.2%	-$1.28K	﹤0.01%	1673
2019 Q4	$533K	Buy	+49,043	New	+$513K	﹤0.01%	1854

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Advisers's ARCT Position: Q1 2026 in Review

Two Sigma Advisers sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 511,043 shares — an estimated $3.13M sold.

Two Sigma Advisers first reported a position in ARCT in Q4 2019 and held it in 10 quarters. The position peaked at $11.2M in Q1 2021. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

Two Sigma Advisers reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 511,043 Arcturus Therapeutics shares in Q1 2026, an estimated $3.13M.
Two Sigma Advisers first reported a position in Arcturus Therapeutics in Q4 2019 and held it in 10 quarters.
Two Sigma Advisers's Arcturus Therapeutics position peaked at $11.2M in Q1 2021.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.